Species distribution and antifungal susceptibility of blood Candida isolates at a tertiary hospital in southern Taiwan, 1999-2006

Mycoses

Volumn 54, Issue 4, 2011, Pages

  Chen, Po Lin ^a,b   Lo, Hsiu Jung ^b,c   Wu, Chi Jung ^a,b   Lee, Hsin Chun ^a,b   Chang, Chia Ming ^a,b   Lee, Nan Yao ^a,b   Wang, An Huei ^b,c   Lin, Wen Liang ^b   Ko, Nai Ying ^a,b   Lee, Ching Chi ^a,b   Ko, Wen Chien ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Antifungal susceptibility; Candida; Candidaemia; Fluconazole

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOOD CULTURE; BLOODSTREAM INFECTION; CANDIDA; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CONTROLLED STUDY; FUNGAL DETECTION; FUNGAL STRAIN; FUNGUS CULTURE; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEDIATRIC WARD; PRIORITY JOURNAL; SPECIES DISTRIBUTION; TAIWAN; TERTIARY HEALTH CARE;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; AZOLES; CANDIDA; CANDIDEMIA; DRUG UTILIZATION; HOSPITALS; HUMANS; INCIDENCE; MICROBIAL SENSITIVITY TESTS; TAIWAN;

CANDIDA; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS;

EID: 79959292848     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2009.01818.x     Document Type: Article

References (31)

1. Edmond MB, Wallace SE, McClish DK et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999; 29: 239-44.
2. Wisplinghoff H, Seifert H, Tallent SM et al. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. Pediatr Infect Dis J 2003; 22: 686-91.
3. Wu CJ, Lee HC, Lee NY et al. Predominance of Gram-negative bacilli and increasing antimicrobial resistance in nosocomial bloodstream infections at a university hospital in southern Taiwan, 1996-2003. J Microbiol Immunol Infect 2006; 39: 135-43.
4. Frank M, Gur E, Givon-Lavi N et al. Nosocomial bloodstream infections in children and adolescents in southern Israel: a 10-year prospective study (1992-2001). Scand J Infect Dis 2005; 37: 177-83.
5. Lyytikainen O, Lumio J, Sarkkinen H et al. Nosocomial bloodstream infections in Finnish hospitals during 1999-2000. Clin Infect Dis 2002; 35: e14-e19.
6. Tortorano AM, Peman J, Bernhardt H et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004; 23: 317-22.
7. Garbino J, Kolarova L, Rohner P et al. Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital. Medicine (Baltimore) 2002; 81: 425-33.
8. Hajjeh RA, Sofair AN, Harrison LH et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004; 42: 1519-27.
9. Marr KA, Seidel K, White TC et al. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181: 309-16.
10. Trick WE, Fridkin SK, Edwards JR et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35: 627-30.
11. Kim SH, Shin JH, Kim EC et al. The relationship between antifungal usage and antifungal susceptibility in clinical isolates of Candida: a multicenter Korean study. Med Mycol 2009; 47: 296-304.
12. Hsueh PR, Lau YJ, Chuang YC et al. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Antimicrob Agents Chemother 2005; 49: 512-7.
13. Pfaller MA, Diekema DJ. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol 2002; 40: 3551-7.
14. Pfaller MA, Messer SA, Hollis RJ et al. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn Microbiol Infect Dis 1999; 33: 217-22.
15. Clinical and Laboratory Standards Institute. Quality Control Minimal Inhibitory Concentration (MIC) Limits for Broth Microdilution and MIC Interpretive Breakpoints. Supplement M44-S1. Wayne, PA: CLSI, 2006.
16. Metwally L, Walker MJ, Coyle PV et al. Trends in candidemia and antifungal susceptibility in a university hospital in Northern Ireland 2001-2006. J Infect 2007; 55: 174-8.
17. Lagrou K, Verhaegen J, Peetermans WE et al. Fungemia at a tertiary care hospital: incidence, therapy, and distribution and antifungal susceptibility of causative species. Eur J Clin Microbiol Infect Dis 2007; 26: 541-7.
18. Colombo AL, Nucci M, Park BJ et al. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 2006; 44: 2816-23.
19. Torres-Rodriguez JM, Alvarado-Ramirez E. In vitro susceptibilities to yeasts using the ATB FUNGUS 2 method, compared with Sensititre Yeast One and standard CLSI (NCCLS) M27-A2 methods. J Antimicrob Chemother 2007; 60: 658-61.
20. Arthington-Skaggs BA, Lee-Yang W, Ciblak MA et al. Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates. Antimicrob Agents Chemother 2002; 46: 2477-81.
21. Lee MK, Williams LE, Warnock DW et al. Drug resistance genes and trailing growth in Candida albicans isolates. J Antimicrob Chemother 2004; 53: 217-24.
22. Yang YL, Wang AH, Wang CW et al. Susceptibilities to amphotericin B and fluconazole of Candida species in Taiwan surveillance of antimicrobial resistance of yeasts 2006. Diagn Microbiol Infect Dis 2008; 61: 175-80.
23. Rex JH, Bennett JE, Sugar AM et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994; 331: 1325-30.
24. Boschman CR, Bodnar UR, Tornatore MA et al. Thirteen-year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center. Antimicrob Agents Chemother 1998; 42: 734-8.
25. Hof H. Is there a serious risk of resistance development to azoles among fungi due to the widespread use and long-term application of azole antifungals in medicine? Drug Resist Updat 2008; 11: 25-31.
26. Cook PP, Catrou PG, Christie JD et al. Reduction in broad-spectrum antimicrobial use associated with no improvement in hospital antibiogram. J Antimicrob Chemother 2004; 53: 853-9.
27. Alfandari S, Bonenfant C, Depretere L et al. Use of 27 parenteral antimicrobial agents in north of France hospitals. Med Mal Infect 2007; 37: 103-7.
28. Clark TA, Slavinski SA, Morgan J et al. Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital. J Clin Microbiol 2004; 42: 4468-72.
29. Girmenia C, Martino P, De Bernardis F et al. Rising incidence of Candida parapsilosis fungemia in patients with hematologic malignancies: clinical aspects, predisposing factors, and differential pathogenicity of the causative strains. Clin Infect Dis 1996; 23: 506-14.
30. Kontoyiannis DP, Vaziri I, Hanna HA et al. Risk factors for Candida tropicalis fungemia in patients with cancer. Clin Infect Dis 2001; 33: 1676-81.
31. Nucci M, Colombo AL. Candidemia due to Candida tropicalis: clinical, epidemiologic, and microbiologic characteristics of 188 episodes occurring in tertiary care hospitals. Diagn Microbiol Infect Dis 2007; 58: 77-82.